Compare LAC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | GERN |
|---|---|---|
| Founded | 2023 | 1990 |
| Country | Canada | United States |
| Employees | N/A | 258 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 911.0M |
| IPO Year | 2023 | N/A |
| Metric | LAC | GERN |
|---|---|---|
| Price | $3.01 | $1.26 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $6.14 | $2.17 |
| AVG Volume (30 Days) | 9.2M | ★ 9.2M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $1.04 |
| 52 Week High | $10.52 | $2.01 |
| Indicator | LAC | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 39.17 |
| Support Level | N/A | $1.24 |
| Resistance Level | $4.04 | $1.30 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 53.57 | 19.35 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.